---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-110119"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2023-10-19T23:59:59+00:00"
generated_at: "2026-06-09T21:07:53.189696+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma Phase 2 migraine trial misses primary endpoint; secondary endpoints statistically significant

## Summary
- Primary endpoint not met: mean MMD reduction of 4.8 days (150U) and 5.0 days (195U) vs 4.2 days placebo; p-values not significant (0.2844, 0.1711).
- Secondary endpoint: 69% of 195U dose achieved ≥50% MMD reduction vs 52% placebo (p=0.0132); 75% reduction significant for both doses.
- Safety profile favorable; Company plans to advance to Phase 3 and request end-of-phase 2 FDA meeting in H1 2024.
- Ongoing Phase 2 for chronic migraine to complete enrollment in Q4 2023; topline data expected in H2 2024.

## SEC filing metadata
- accession: 0001104659-23-110119
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2023-10-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000110465923110119/0001104659-23-110119-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000110465923110119/tm2328542d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-110119
- JSON: https://secwatch.observer/filing/0001104659-23-110119.json
- Plain text: https://secwatch.observer/filing/0001104659-23-110119.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.